Drug updated on 9/4/2024
Dosage Form | Extended-release tablet (oral; 6mg, 12mg, 24mg); Tablet (oral; 6 mg, 9 mg, 12 mg) |
Drug Class | Vesicular monoamine transporter 2 inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with chorea associated with Huntington’s disease.
- For the treatment of adult patients with tardive dyskinesia.
Latest News
Summary
- Austedo (deutetrabenazine) is indicated for the treatment of adult patients with chorea associated with Huntington's disease and for the treatment of adult patients with tardive dyskinesia.
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- Effectiveness of VMAT-2 inhibitors in psychosis: VMAT-2 inhibitors, including deutetrabenazine, were found to be more effective than placebo for achieving a 'slight improvement' in psychosis (RR = 1.77, 95% CI 1.03, 3.04), but not for 'moderate improvement' (RR 2.81, 95% CI 0.27, 29.17). The efficacy was comparable to active comparators for both 'slight improvement' (RR 1.05, 95% CI 0.6, 1.81) and 'moderate improvement' (RR 1.11, 95% CI 0.51, 2.42).
- Deutetrabenazine and valbenazine in tardive dyskinesia: Deutetrabenazine (12 mg twice daily) demonstrated short-term efficacy in reducing tardive dyskinesia symptoms, similar to valbenazine, which showed a ≥50% reduction in Abnormal Involuntary Movement Scale score at 80 mg/day in both short-term and long-term studies. However, more long-term efficacy data for deutetrabenazine are needed.
- General efficacy of new VMAT inhibitors: The strongest evidence for treating tardive dyskinesia comes from new VMAT inhibitors, including deutetrabenazine, though further long-term efficacy data are required.
- There were no specific adverse effects or safety concerns detailed for VMAT-2 inhibitors, including deutetrabenazine, in the studies reviewed.
- Both deutetrabenazine and valbenazine demonstrated tolerability in clinical trials; however, more long-term safety data are required for deutetrabenazine.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Austedo (deutetrabenazine) Prescribing Information. | 2023 | Teva Pharmaceuticals USA Inc., Parsippany, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis. | 2023 | Psychopharmacology |
A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. | 2019 | Therapeutic Advances in Psychopharmacology |
Treatment recommendations for tardive dyskinesia. | 2019 | The Canadian Journal of Psychiatry |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Movement disorders therapeutic class review (TCR). | 2022 | Texas Health and Human Services |
The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia third edition. | 2021 | American Psychiatric Association |
International guidelines for the treatment of Huntington's disease. | 2019 | Frontiers in Neurology |